LEVI 04

Drug Profile

LEVI 04

Alternative Names: p75NTR-Fc

Latest Information Update: 18 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Developer Levicept
  • Class Analgesics; Recombinant fusion proteins
  • Mechanism of Action Nerve growth factor receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Pain

Most Recent Events

  • 28 Jul 2017 Phase-I clinical trials in Pain (associated with osteoarthritis of the knee) in United Kingdom (Parenteral) (NCT03227796)
  • 26 Jul 2017 Levicept plans a phase I trial for Pain (NCT03227796)
  • 30 Sep 2013 Levicept acquires LEVI-04 from Pfizer prior to September 2013
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top